Free Trial
NASDAQ:FHTX

Foghorn Therapeutics (FHTX) Stock Price, News & Analysis

Foghorn Therapeutics logo
$5.52 +0.48 (+9.52%)
As of 11:05 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Foghorn Therapeutics Stock (NASDAQ:FHTX)

Key Stats

Today's Range
$5.06
$5.56
50-Day Range
$4.32
$6.50
52-Week Range
$2.94
$10.25
Volume
34,854 shs
Average Volume
128,228 shs
Market Capitalization
$312.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67
Consensus Rating
Buy

Company Overview

Foghorn Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

FHTX MarketRank™: 

Foghorn Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 611th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Foghorn Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Foghorn Therapeutics has received no research coverage in the past 90 days.

  • Read more about Foghorn Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Foghorn Therapeutics are expected to grow in the coming year, from ($1.55) to ($1.02) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Foghorn Therapeutics is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Foghorn Therapeutics is -4.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Foghorn Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    3.14% of the float of Foghorn Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Foghorn Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Foghorn Therapeutics has recently decreased by 2.08%, indicating that investor sentiment is improving.
  • Dividend Yield

    Foghorn Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Foghorn Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.14% of the float of Foghorn Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Foghorn Therapeutics has a short interest ratio ("days to cover") of 7.
  • Change versus previous month

    Short interest in Foghorn Therapeutics has recently decreased by 2.08%, indicating that investor sentiment is improving.
  • Search Interest

    5 people have searched for FHTX on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Foghorn Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.58% of the stock of Foghorn Therapeutics is held by insiders.

  • Percentage Held by Institutions

    61.55% of the stock of Foghorn Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Foghorn Therapeutics' insider trading history.
Receive FHTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Foghorn Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FHTX Stock News Headlines

I trusted Trump and got screwed
Porter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning about a dangerous flaw in America’s financial system for 15 years, he believed Trump might fix it. Instead, he says the problem has only grown worse. In his new emergency broadcast, Breaking Point, Porter reveals why this flaw may now be irreversible—and how it could gut retirement accounts, trigger mass wealth destruction, and blindside hard-working investors.tc pixel
Foghorn Therapeutics Inc (FHTX) - Investing.com
See More Headlines

FHTX Stock Analysis - Frequently Asked Questions

Foghorn Therapeutics' stock was trading at $4.72 at the beginning of 2025. Since then, FHTX shares have increased by 16.9% and is now trading at $5.52.

Foghorn Therapeutics Inc. (NASDAQ:FHTX) released its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.03. The company earned $7.56 million during the quarter, compared to the consensus estimate of $7.62 million.

Foghorn Therapeutics (FHTX) raised $120 million in an initial public offering on Friday, October 23rd 2020. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Morgan Stanley and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Top institutional investors of Foghorn Therapeutics include Raymond James Financial Inc. (4.19%), Geode Capital Management LLC (1.43%), Ameriprise Financial Inc. (0.20%) and Panagora Asset Management Inc. (0.12%). Insiders that own company stock include Samuel Agresta and Carlos Costa.
View institutional ownership trends
.

Shares of FHTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Foghorn Therapeutics investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX), Meta Platforms (META) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/05/2025
Today
8/21/2025
Next Earnings (Estimated)
11/03/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:FHTX
CIK
1822462
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$14.00
Low Price Target
$9.00
Potential Upside/Downside
+111.6%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$86.62 million
Net Margins
-311.90%
Pretax Margin
-311.90%
Return on Equity
N/A
Return on Assets
-28.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.62
Quick Ratio
2.62

Sales & Book Value

Annual Sales
$22.60 million
Price / Sales
12.61
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-3.71

Miscellaneous

Outstanding Shares
56,530,000
Free Float
52,245,000
Market Cap
$284.91 million
Optionable
Optionable
Beta
3.05

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:FHTX) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners